OncoMatch/Clinical Trials/NCT07125872
Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
Is NCT07125872 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies CD19 t-haNK- IV Administration for relapsed b-cell non hodgkin lymphoma.
Treatment: CD19 t-haNK- IV Administration — Open Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination with Rituximab in subjects with Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: cytotoxic chemotherapy
Have completed ≥2 lines of cytotoxic chemotherapy
Must have received: anti-CD20 antibody (rituximab)
Have received rituximab or another anti-CD20 antibody
Cannot have received: anti-CD20 antibody
Exception: less than 2 weeks prior to cell infusion
Anti-CD20 antibody treatment less than 2 weeks prior to cell infusion
Cannot have received: allogeneic hematopoietic stem-cell transplantation
Exception: requiring ongoing systemic graft versus host disease (GvHD) therapy
History of allogeneic hematopoietic stem-cell transplantation (HSCT) requiring ongoing systemic graft versus host disease (GvHD) therapy
Cannot have received: allograft organ transplant
Exception: requiring immunosuppression
History of receiving allograft organ transplant requiring immunosuppression
Lab requirements
Blood counts
ANC ≥ 1000 cells/mm3; Platelet count ≥ 100,000 cells/mm3
Kidney function
Serum creatinine < 160 µmol/L
Liver function
Total bilirubin < 1.5 × ULN (unless Gilbert's syndrome or indirect hyperbilirubinemia); AST/ALT < 2.5 × ULN; ALP < 2.5 × ULN (or < 5 × ULN with bone metastases)
Inadequate organ function, evidenced by ... ANC < 1000 cells/mm3. Platelet count < 100,000 cells/mm3. Total bilirubin ≥ 1.5 × ULN (unless ...). AST/ALT ≥ 2.5 × ULN. ALP ≥ 2.5 × ULN (or ≥ 5 × ULN in participants with bone metastases). Serum creatinine ≥ 160 µmol/L.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07125872 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-CD20 antibody, allogeneic hematopoietic stem-cell transplantation, allograft organ transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages